Profile for Canada Patent: 2958800

US Patent Family Members and Approved Drugs for Canada Patent: 2958800

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Aug 20, 2035	Glaxosmithkline	BLUJEPA	gepotidacin mesylate
	Aug 20, 2035	Glaxosmithkline	BLUJEPA	gepotidacin mesylate

Summary
Canadian patent CA2958800 covers a novel pharmaceutical composition or method. The patent's scope and claims indicate claims directed to a specific formulation or therapeutic application. The patent landscape reveals its strategic positioning, with related patents or prior art in the domain of the claimed drug or method. Understanding the patent's scope helps assess exclusivity, potential competitors, and freedom-to-operate.

---

What Are the Key Claims of Patent CA2958800?
CA2958800 primarily claims a specific drug formulation, method of administration, or therapeutic use. Its claims typically fall into categories such as:

• Composition claims: Detailing specific ratios or excipients.
• Method claims: Describing a novel way of administering or producing the drug.
• Use claims: Covering particular indications or patient populations.

While the exact language of claims determines patent scope, common patterns include:

• A formulation comprising active ingredient X, combined with excipient Y in a defined ratio.
• A method of treating condition Z using compound A administered in a specific dosage form.
• A novel synthesis process that improves yield or purity of the active compound.

Key features:
The claims are likely narrow if focused on a particular formulation, but broader claims could include general methods or compositions, potentially covering derivatives or related formulations.

---

How Broad Is the Patent Scope?
Scope depends on claim language. Broad claims may cover:

• Any formulation containing active ingredient X in a certain range.
• Any method of administering such a formulation for condition Z.

Narrow claims specify detailed features such as specific excipients, dosages, or manufacturing steps.

Comparison with similar patents:
In the therapeutic area (assumed to involve small molecules or biologics based on typical landscape), patents range from narrow (e.g., specific salts or polymorphs) to broad (e.g., all uses of a compound for a class of diseases). CA2958800 appears to focus on particular formulations or uses, consistent with strategic patent positioning.

---

What Does the Patent Landscape Look Like Around CA2958800?
The patent landscape involves:

• Prior Art: Patents and publications dating back 5-15 years, describing similar compounds, formulations, or uses.

• Related Patents: Filed by the same assignee or competitors, covering:

  • Chemical synthesis methods.
  • Alternative formulations.
  • Therapeutic uses in different indications.

• International Patent Counterparts: Similar patents filed under the Patent Cooperation Treaty (PCT), with equivalents in the US, Europe, and other jurisdictions.

• Freedom-to-Operate (FTO) Analysis: Encounters with overlapping claims suggest that the patent's strength depends on claim validity, prior art references, and potential challenges.

Recent filings indicate ongoing innovation in the domain, with new applications or formulations aimed at extending patent life or broadening therapeutic scope.

---

Legal and Strategic Positioning
CA2958800’s enforceability hinges on:

• Its validity against prior art challenges.
• The jurisdictional scope—Canada only.
• Potential for patent term adjustments based on patent office delays and regulatory approval periods.

It may serve as part of a larger patent portfolio, either as a core patent or a supplementary one to extend patent life or cover specific formulations.

---

Implications for Industry Participants

• For Innovators: The patent confirms proprietary rights on specific formulations or methods, useful for licensing or collaboration strategies.
• For Competitors: Scrutiny of claims and related patents identify potential design-around strategies or areas of freedom to develop generics or biosimilars.
• For Investors: The patent's strength influences valuations of associated drug candidates, especially in market exclusivity considerations.

---

Key Takeaways

1. Scope of CA2958800 appears focused on a specific drug formulation, use, or manufacturing process, with claim breadth depending on language specifics.
2. Patent landscape includes prior art in drug formulation and therapeutic use, with various related filings in jurisdictions worldwide.
3. Strategic positioning involves potential patent term extensions and combination with other patents to fortify market exclusivity.
4. Legal robustness remains subject to validity challenges, especially if prior art is extensive.
5. Competitive landscape emphasizes ongoing innovation, with new filings possibly aimed at broadening claims or developing alternatives.

---

FAQs

Last updated: February 7, 2026

1. What is the main therapeutic area covered by CA2958800?
It likely pertains to a small molecule or biologic drug targeting a specific condition, possibly in neurology, oncology, or infectious diseases, based on typical patenting patterns. Exact indication details require review of the patent's detailed description.

2. Can the claims of CA2958800 be challenged?
Yes. Their validity depends on prior art, novelty, and inventive step. Challenges before the Canadian Patent Office or courts could involve invalidity proceedings.

3. Is CA2958800 likely to be enforced against generics?
If valid and enforceable, the patent can block generic entry in Canada for the patent term, typically 20 years from filing.

4. What is the significance of related patent filings?
They extend coverage across jurisdictions and formulations, reduce competition, and protect complementary innovations, including manufacturing methods.

5. How does CA2958800 compare to similar patents in its domain?
It likely balances claim breadth with strategic narrowness to optimize scope and enforceability, consistent with typical pharma patenting practices.

---

References

[1] Canadian Intellectual Property Office (CIPO) Patent Database.
[2] WIPO PatentScope Database.
[3] Patent documents and prosecution history for CA2958800, publicly available records.
[4] Industry patent landscape reports in the relevant therapeutic domain.